Bever, Katherine M.
Thomas, Dwayne L. II
Zhang, Jiajia
Diaz Rivera, Ernie A.
Rosner, Gary L.
Zhu, Qingfeng
Nauroth, Julie M.
Christmas, Brian
Thompson, Elizabeth D.
Anders, Robert A.
Judkins, Carol
Liu, Meizheng
Jaffee, Elizabeth M.
Ahuja, Nita
Zheng, Lei
Azad, Nilofer S. http://orcid.org/0000-0003-0125-2405
Clinical trials referenced in this document:
Documents that mention this clinical trial
A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint
https://doi.org/10.1186/s13148-021-01014-8
Funding for this research was provided by:
Zhang Family Gift Fund
Susie's Cause Colon Cancer Foundation
Sidney Kimmel Comprehensive Cancer Center (P30 CA006973)
Article History
Received: 24 November 2020
Accepted: 13 January 2021
First Online: 2 February 2021
Ethics approval and consent to participate
: The study protocol was approved by the institutional review board of the Johns Hopkins School of Medicine and was conducted according to the Declaration of Helsinki and the guidelines for Good Clinical Practice. All patients signed a written informed consent before the conduct of any study procedures and after a full explanation of the study to the patient by the study investigator.
: Not applicable.
: Through a licensing agreement with Aduro Biotech, Dr. Jaffee and the Johns Hopkins University have the potential to receive royalties on the sale of GVAX. N. Ahuja has received grant funding from Cepheid and Astex and has served as consultant to Ethicon. She has licensed methylation biomarkers to Cepheid. No potential conflict of interest were disclosed by the other authors.